R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the fondazione italiana linfomi

Journal of Clinical Oncology

Volumn 31, Issue 12, 2013, Pages 1506-1513

  Federico, Massimo ^a   Luminari, Stefano ^a   Dondi, Alessandra ^a   Tucci, Alessandra ^b   Vitolo, Umberto ^c   Rigacci, Luigi ^d   Raimondo, Francesco Di ^e   Carella, Angelo Michele ^f   Pulsoni, Alessandro ^g   Merli, Francesco ^h   Arcaini, Luca ⁱ   Angrilli, Francesco ^j   Stelitano, Caterina ^k   Gaidano, Gianluca ^l   Dell'Olio, Matteo ^m   Marcheselli, Luigi ^a   Franco, Vito ⁿ   Galimberti, Sara ^o   Sacchi, Stefano ^a   Brugiatelli, Maura ^p  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c SC di Cardiologia Ospedaliera   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e Ospedale 'Ferrarotto'   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PAVIA   (Italy)

^j SPIRITO SANTO HOSPITAL   (Italy)

^k Department of Endocrinology and Diabetology   (Italy)

^l UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^m CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

^o UNIVERSITY HOSPITAL OF PISA   (Italy)

^p Azienda Ospedaliera   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM GRADING; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; VIDARABINE; VINCRISTINE;

EID: 84876578455     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.0866     Document Type: Article

References (40)

1. Fisher RI, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23: 8447-8452, 2005
2. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as firstline treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
3. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
4. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007 (Pubitemid 46972781)
5. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824- 4831, 2008
6. Rigacci L, Federico M, Martelli M, et al: The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma 44:1911-1917, 2003 (Pubitemid 37369623)
7. Kimby E, Bjǒrkholm M, Gahrton G, et al: Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5:67-71, 1994 (suppl 2) (Pubitemid 24061323)
8. Solal-Céligny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as firstline treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996 (Pubitemid 26051015)
9. Coiffier B, Neidhardt-Bérard EM, Tilly H, et al: Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study - Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 10:1191-1197, 1999 (Pubitemid 29533569)
10. Hagenbeek A, Eghbali H, Monfardini S, et al: Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 24:1590- 1596, 2006 (Pubitemid 46646221)
11. Friedberg JW, Taylor MD, Cerhan JR, et al: Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 27:1202-1208, 2009
12. Federico M, Bellei M, Marcheselli L, et al: Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555- 4562, 2009
13. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 36:69-86, 2000
14. Barosi G, Carella A, Lazzarino M, et al: Management of nodal indolent (non marginal-zone) non- Hodgkin's lymphomas: Practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 90: 1236-1257, 2005 (Pubitemid 41379052)
15. Solal-Cé ligny P, Roy P, Colombat P, et al: Follicular Lymphoma International Prognostic Index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
16. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999 (Pubitemid 29162950)
17. Hryniuk WM: Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14:65-74, 1987 (Pubitemid 17053480)
18. Sankoh AJ, Huque MF, Dubey SD: Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16: 2529-2542, 1997 (Pubitemid 27490059)
19. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001 (Pubitemid 32322245)
20. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Cox D: Regression models and life tables. J R Stat Soc B 34:187-202, 1972
22. Schoenfeld D: Partial residuals for proportional hazard regression model. Biometrika 69:239- 241, 1982
23. Armitage P, Berry G: Statistical Methods in Medical Research (ed 2). Oxford, United Kingdom, Blackwell Scientific Publications, 1987
24. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
25. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
26. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993 (Pubitemid 23105672)
27. Baldini L, Brugiatelli M, Luminari S, et al: Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol 21:1459-1465, 2003 (Pubitemid 46594096)
28. Nastoupil L, Sinha R, Byrtek M, et al: A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Blood 118, 2011 (abstr 97)
29. McLaughlin P, Rodriguez M, Hagemeister F, et al: Stage IV indolent lymphoma: A randomized trial of concurrent vs. sequential FND (fludarabine, mitoxantrone, dexamethasone) and rituximab, with interferon maintenance. Proc Am Soc Clin Oncol 22, 2003 (abstr 2269)
30. Zinzani PL, Pulsoni A, Perrotti A, et al: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as frontline treatment for patients with follicular lymphoma. J Clin Oncol 22:2654-2661, 2004 (Pubitemid 41103753)
31. Vitolo U, Ladetto M, Boccomini C, et al: Brief chemoimmunotherapy R-FND with rituximab consolidation followed by randomization between rituximab maintenance vs. observation as first line treatment in elderly patients with advanced follicular lymphoma (FL): Final results of a prospective randomized trial by Italian Lymphoma Foundation (FIL). Blood 118, 2011 (abstr 777)
32. Sacchi S, Marcheselli L, Bari A, et al: Secondary malignancies after treatment for indolent non- Hodgkin's lymphoma: A 16-year follow-up study. Haematologica 93:398-404, 2008 (Pubitemid 351398641)
33. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. J Clin Oncol 30:6s, 2012 (suppl; abstr 3)
34. Salles G, Seymour JF, Offner F, et al: Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. Lancet 377:42-51, 2011
35. Samaniego F, Hagemeister F, Mclaughlin P, et al: High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 29:511s, 2011 (suppl; abstr 8030)
36. Fowler NH, McLaughlin P, Kwak L, et al: Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 27:445s, 2009 (suppl; abstr 8548)
37. Ladetto M, De Marco F, Benedetti F, et al: Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004-4013, 2008
38. Dupuis J, Meignan M, Julian A, et al: Significant prognostic impact of [18F]fluorodeoxyglucose- PET scan performed during and at the end of treatment with R-CHOP in high-tumor mass follicular lymphoma patients: A GELA-GOELAMS study. Blood 118, 2011 (abstr 877)
39. Luminari S, Versari A, Quaresima M, et al: Role of FDG-PET as prognostic indicator in patients with follicular lymphoma (FL) after immunochemotherapy induction: A retrospective study from the Fondazione Italiana Linfomi. Blood 118, 2011 (abstr 2636)
40. Trotman J, Fournier M, Lamy T, et al: Positron emission tomography-computed tomography (PETCT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29:3194-3200, 2011